Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer ... last year after a trial that was supposed ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Electronic "nose" analysis of exhaled breath achieved 80-90% accuracy for detecting lung cancer in patients with suspicious ...

Researchers from Touro University and Lovelace Biomedical are Developing an Innovative Treatment for Lung Cancer ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung ...

“Imfinzi has helped change the treatment landscape and achieved multiple positive phase 3 trials for patients with earlier stages of lung cancer,” she added. “We are committed to addressing ...

The efficacy of bsAbs in clinical trials has led to their approval for both hematologic ... ES-SCLC, early-stage small cell lung cancer; FDA, US Food and Drug Administration; HLA, human leukocyte ...

Research Pinpoints Weakness in Lung Cancer's Defenses Feb. 10, 2025 — Scientists uncover an enzyme that boosts cancer cell metabolism to fuel growth. The enzyme, GUK1, supports metabolism in ...

“I think this is a very exciting study,” said Patrick Hwu, president of the Moffitt Cancer Center in Tampa ... qualified for one of Rosenberg’s trials. She marveled at the quality ...